Advances in the preclinical testing of cancer therapeutic hypotheses

@article{Caponigro2011AdvancesIT,
  title={Advances in the preclinical testing of cancer therapeutic hypotheses},
  author={Giordano Michael. Caponigro and William R Sellers},
  journal={Nature Reviews Drug Discovery},
  year={2011},
  volume={10},
  pages={179-187}
}
The genetic and epigenetic underpinnings of cancer are becoming increasingly clear owing to impressive and well-coordinated ventures occurring worldwide. As our understanding of the molecular alterations driving human cancer increases, there is an opportunity to direct the clinical application of cancer therapeutics with improved accuracy. The often empirical treatment of cancer — which was initially based on inhibiting DNA synthesis and cellular division — while having led to a number of… CONTINUE READING
BETA

Figures and Topics from this paper.

Explore Further: Topics Discussed in This Paper

Citations

Publications citing this paper.
SHOWING 1-10 OF 45 CITATIONS

Inhibitors of the tankyrases, triple-function targets in the cancer cell

VIEW 4 EXCERPTS
CITES BACKGROUND & METHODS
HIGHLY INFLUENCED

Organoid cultures for the analysis of cancer phenotypes.

  • Current opinion in genetics & development
  • 2014
VIEW 3 EXCERPTS
CITES BACKGROUND
HIGHLY INFLUENCED

New Insights into Toxicity and Drug Testing

VIEW 5 EXCERPTS
CITES BACKGROUND
HIGHLY INFLUENCED

Organoid technology and applications in cancer research

  • Journal of hematology & oncology
  • 2018
VIEW 2 EXCERPTS
CITES BACKGROUND

Tumor xenograft modeling identifies an association between TCF4 loss and breast cancer chemoresistance

Gorka Ruiz de Garibay, F. J. Nuño Mateo, +19 authors Miguel Angel Pujana
  • Disease models & mechanisms
  • 2018
VIEW 1 EXCERPT
CITES BACKGROUND

References

Publications referenced by this paper.
SHOWING 1-10 OF 95 REFERENCES

Clinical efficacy of a RAF inhibitor needs broad target blockade in BRAF-mutant melanoma

G Bollag
  • Nature 467,
  • 2010

Phase I clinical trial of the CYP17 inhibitor abiraterone acetate demonstrating clinical activity in patients with castration-resistant prostate cancer who received prior ketoconazole therapy

Ryan, J C.
  • J. Clin. Oncol
  • 2010

Similar Papers

Loading similar papers…